Affymax Plunges After Recall of Omontys due to Reactions
This article is for subscribers only.
Affymax Inc. fell the most ever after the drugmaker and partner Takeda Pharmaceutical Co. voluntarily recalled an anemia treatment for kidney dialysis patients after reports of three fatal reactions.
Affymax declined 85 percent to $2.42 at the close in New York, the biggest one-day drop since the stock began trading in December 2006. The shares of the Palo Alto, California-based company lost 77 percent in the past 12 months.